Cases
Nabriva Therapeutics plc (NBRV)
Securities Class Action
Overview
Overview
- Date:
- 5/2/2019
- Company Name:
- Nabriva therapeutics plc
- Stock Symbol:
- NBRV
- Status:
- Closed/Complete
NEW YORK, May 2, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Nabriva Therapeutics plc (NASDAQ: NBRV). Our investigation concerns whether Nabriva has violated the federal securities laws and/or engaged in other unlawful business practices.
On April 30, 2019, Nabriva disclosed receipt of a Complete Response Letter (“CRL”) from the FDA for the company’s New Drug Application (“NDA”) seeking marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva advised investors that “[t]he CRL requests that Nabriva address issues related to facility inspections and manufacturing deficiencies at one of Nabriva’s contract manufacturers prior to the FDA approving the NDA.”
On this news, Nabriva’s share price fell by more than 27%, closing at $2.17 on May 1, 2019.
If you purchased or otherwise acquired Nabriva shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On April 30, 2019, Nabriva disclosed receipt of a Complete Response Letter (“CRL”) from the FDA for the company’s New Drug Application (“NDA”) seeking marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva advised investors that “[t]he CRL requests that Nabriva address issues related to facility inspections and manufacturing deficiencies at one of Nabriva’s contract manufacturers prior to the FDA approving the NDA.”
On this news, Nabriva’s share price fell by more than 27%, closing at $2.17 on May 1, 2019.
If you purchased or otherwise acquired Nabriva shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.